DOCSLIB.ORG

Advances in Targeted Therapies for Metastatic Colorectal Cancer

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Advances in Targeted Therapies for Metastatic Colorectal Cancer REVIEW Advances in targeted therapies for metastatic colorectal cancer Colorectal cancer is one of the most frequently diagnosed malignancies in men and women and despite recent advances the prognosis of metastatic colorectal cancer remains poor. A better understanding of the molecular pathways that characterize tumor growth has provided novel targets in cancer therapy. Several proteins have been implicated as having a crucial role in metastatic colorectal cancer. Targets are defined according to their cellular localization, such as membrane receptor targets, intracellular signaling targets and protein kinases that regulate cell division. In the last 5 years, cetuximab, panitumumab and bevacizumab have been approved for the treatment of metastatic colorectal cancer and emerging data on the clinical development of new drugs, other than EGF-receptor and VEGF inhibitors, are likely to provide novel opportunities in the treatment of this malignancy. KEYWORDS: metastatic colorectal cancer molecular cancer biology Jose Perez-Garcia, targeted therapies Jaume Capdevila, Teresa Macarulla, Colorectal cancer (CRC) is one of the most fre- factors. One of the most important regulators Francisco Javier Ramos, quent diagnosed cancers in men and women. In of this process is VEGF and VEGFR. VEGF is Elena Elez, recent years, CRC mortality has progressively a 45-kDa homodimer that belongs to a family Manuel Ruiz-Echarri & decreased, probably owing to the availability of of growth factors comprising six different gly- Josep Tabernero† earlier diagnosis through screening, improve- coproteins: VEGF-A (commonly referred to as †Author for correspondence: ments in surgical therapies and both chemo- VEGF), -B, -C, -D, -E, and PlGF. Owing to its Medical Oncology Department, therapy and radiotherapy approaches. Better central role in tumor-associated angiogenesis, Vall d’Hebron University knowledge of the molecular cancer biology has VEGF has emerged as an attractive and central Hospital, P. Vall d’Hebron also contributed to the better outcomes of the therapeutic target in CRC. 119–129 08035, Barcelona, metastatic CRC (mCRC) population, but there Bevacizumab is a humanized anti-VEGF Spain is a need to optimize and define the best use of monoclonal antibody (mAb) that binds and neu- Tel.: +34 932 746 085 these new approaches. tralizes human VEGF [1]. In 2004, bevacizumab Fax: +34 932 746 059 Targets are defined according to their cellular was approved for first-line treatment of mCRC [email protected] localization, such as membrane receptor targets patients. Bevacizumab improved response rate (e.g., EGF-receptor [EGFR], VEGF receptor (RR), median progression-free survival (mPFS) [VEGFR], IGF-receptor [IGFR], PDGF-receptor and overall survival (OS) when given in com- [PDGFR], TNF-related apoptosis-inducing ligand bination with irinotecan-based therapy [2]. The receptor [TRAIL-R] and hepatocyte growth fac- results of the NO16966 trial that evaluated the tor receptor or C-Met), intracellular signaling addition of bevacizumab to leucovorin/5-fluo- targets (e.g., Ras/Raf/MAPK pathway, phospha- rouracil/oxaliplatin (FOLFOX) or capecitabine/ tidylinositol-3-kinase [PI3K]/AKT/mammalian oxaliplatin (XELOX) have recently been pub- target of rapamycin [mTOR] pathway, src kinase lished. The aim of the study was to demonstrate and p53/Hdm2) and protein kinases that regulate the noninferiority of XELOX versus FOLFOX cell division, such as aurora kinases (AKs) and and the superiority of bevacizumab when added polo-like kinases (Plks) (FIGURE 1). to oxaliplatin-based treatment. Bevacizumab In this review, we focus on the advances and added statistically significant improvement in development status of targeted therapies in the mPFS (8 vs 9.4 months, respectively; p = 0.0023; treatment of mCRC. hazard ratio [HR]) = 0.83) [3]. In second-line therapy, the Phase III E3200 study compared Agents targeting membrane receptors FOLFOX plus high-dose bevacizumab (10 mg/ VEGFR inhibitors kg), FOLFOX alone or bevacizumab alone and The regulation of angiogenesis is a complex, showed a statistically significant improvement in multistep process resulting from a dynamic bal- OS, mPFS and RR for the combination arm [4]. ance between proangiogenic and antiangiogenic After these results, bevacizumab was approved 10.2217/THY.09.11 © 2009 Future Medicine Ltd Therapy (2009) 6(3), 321–333 ISSN 1475-0708 321 REVIEW Perez-Garcia, Capdevila, Macarulla et al. Advances in targeted therapies for metastatic colorectal cancer REVIEW Integrins Ligands Cell (EGF, TGF-α, IGF) Growth factor receptor surface α (EGFR, IGFR, PDGFR) TRAIL-R1/R2 β uPA [P14P, P14,5, P ] [P13, 4P P13, 4, 5, P ] 2 2 2 Sos Grb2 PTEN Akt P13K K K C-src Shc C-src Ras Procaspase-8,10 NF-κβ mTOR FKHR GSK-3 Bad Raf uPAR Intracellular signaling Caspase-8,10 STAT MEK1/2 p27 Effector caspase 1 MAPK Apoptosis Cell transcription/ cell cycle progression Transcription factor Cellular responses activation Invasion Angiogenesis Survival Proliferation metastasis Figure 1. Scheme of intracellular signal transduction pathways. Ligands bind to the extracellular domain of membrane receptors, which are phosphorylated, leading to activation of several cytoplasmatic messengers, which activate transcription factors in the nucleus. The activation of transcription factors in the nucleus involves some target genes which are implicated in the proliferation, angiogenesis, apoptosis and tumor invasion processes. EGFR: EGF-receptor; FKHR: forkhead transcription factor; GRB2: growth factor receptor-bound protein 2; IGFR: IGF-receptor; mTOR: Mammalian target of rapamycin; PDGFR: PDGF-receptor; PI34P2: Phosphatidylinositol (3,4) biphosphate; PI345P3: Phosphatidylinositol (3,4,5) triphosphate; PI3K: Phosphatidylinositol 3-kinase; PTEN: Phosphatase and tensin homolog; SHC: Src homology 2 domain-containing transforming protein; SOS: Son of sevenless protein; STAT: Signal transducers and activators of transcription protein; TRAIL: TNF-related apoptosis-inducing ligand; TRAIL-R: TRAIL-receptor; uPA: Urokinase-type plasminogen activator; uPAR: Urokinase-type plasminogen activator receptor. in second-line therapy for mCRC patients. second-line chemotherapy after failing first-line The observational cohort study Bevacizumab chemotherapy in combination with bevacizumab Regimens Investigation of Treatment Effects and in patients with mCRC. Safety (BRITE) has recently been published and Hypertension is the most common beva- suggested that continuation of VEGF inhibition cizumab-related toxicity. Other toxicities of with bevacizumab beyond initial progression antiangiogenic therapy are summarized in BOX 1. could prolong OS [5]. Two ongoing prospective A variety of small-molecule tyrosine kinases randomized trials (ML18147 and Southwest (TKIs) targeting the VEGFRs are being devel- Oncology Group [SWOG] S0600) are com- oped, such as PTK-787 (vatalanib), SU-5416 paring the value of adding bevacizumab to (semaxanib), SU-11248 (sunitinib), AZD-2171 (cediranib), BAY-43–9006 (sorafenib) and Box 1. Anti-VEGF adverse effects. ZD-6474 (vandetanib). Of these, PTK-787 Hypertension is the most advanced VEGFR TKI in clinical Proteinuria development. The CONFIRM-1 study failed to Bleeding demonstrate an advantage in PFS when PTK-787 Thrombotic effects was added to FOLFOX in first-line treatment[6] . Wound healing The CONFIRM-2 study evaluated the efficacy Gastrointestinal perforation of PTK-787 in combination with FOLFOX 322 Therapy (2009) 6(3) future science group REVIEW Perez-Garcia, Capdevila, Macarulla et al. Advances in targeted therapies for metastatic colorectal cancer REVIEW versus FOLFOX alone in 855 patients with iri- bevacizumab plus chemotherapy (XELOX) with notecan-refractory mCRC. PFS was significantly or without cetuximab. Similarly, the combina- longer in the PTK-787 arm but no improvement tion of cetuximab and bevacizumab resulted in OS was demonstrated [7]. A metanalysis of the in a shorter mPFS [14]. The results of these two CONFIRM-1 and CONFIRM-2 studies showed studies suggested that there is a lack of biological that PTK-787 significantly improved PFS in synergistic effect between mAbs against EGFR patients with high lactate dehydrogenase levels (panitumumab or cetuximab) and bevacizumab [8]. Whether lactate dehydrogenase could serve in combination with chemotherapy in first-line as a surrogate marker for hypoxia and a predic- therapy of mCRC patients. A National Cancer tive factor of response to antiangiogenic therapy Institute-sponsored study (Cancer and Leukemia remains nuclear [9]. SU-11248 alone has not dem- Group B [CALGB]/SWOG 80404) comparing onstrated objective responses in refractory mCRC the addition of cetuximab, bevacizumab or both patients [10]. A randomized Phase IIb study of to standard chemotherapy – either FOLFOX or FOLFOX plus SU-11248 versus FOLFOX FOLFIRI, at the physician’s choice – in chemona- plus bevacizumab and a Phase III study of ive mCRC patients is ongoing, and should help to leucovorin/5-fluorouracil/irinotecan (FOLFIRI) define the role of these two agents used in combi- with or without SU-11248 in first-line mCRC nation in the therapeutic armamentarium. patients are currently ongoing. At the 2008 Small molecule dual inhibitors of VEGFR American Society of Oncology (ASCO) meet- and EGFR, such as vandetanib (ZD-6474) ing, a Phase II randomized study (HORIZON-1) or AEE-788, are under clinical development. of cediranib with FOLFOX versus bevacizu- A Phase II randomized study of two doses of mab with FOLFOX in patients
Load more

Recommended publications
  • Regimen Reference Order – GAST – FOLFIRI
    ADULT Updated: January 8, 2018 Regimen Reference Order – GAST – FOLFIRI ARIA: GAST – [FOLFIRI] Planned Course: Every 14 days until disease progression or unacceptable toxicity Indication for Use: Colorectal Cancer Metastatic CVAD: Required (Ambulatory Pump) Proceed with treatment if: ANC equal to or greater than 1.5 x 109/L AND Platelets equal to or greater than 100 x 109/L Contact Physician if parameters not met SEQUENCE OF MEDICATION ADMINISTRATION Pre-treatment Requirements Drug Dose CCMB Administration Guideline Not Applicable Treatment Regimen – GAST - FOLFIRI Establish primary solution 500 mL of: normal saline Drug Dose CCMB Administration Guideline ondansetron 16 mg Orally 30 minutes pre-chemotherapy dexamethasone 12 mg Orally 30 minutes pre-chemotherapy atropine 0.6 mg IV Push over 2 – 3 minutes pre-irinotecan May be repeated once if diarrhea occurs during irinotecan infusion irinotecan 180 mg/m2 IV in 500 mL D5W over 90 minutes irinotecan can be infused at the same time as leucovorin through a Y site leucovorin 400 mg/m2 IV in 500 mL D5W over 90 minutes fluorouracil 400 mg/m2 IV Push over 5 minutes fluorouracil 2400 mg/m2 IV in D5W continuously over 46 hours by ambulatory infusion device All doses will be automatically rounded that fall within the DSG Approved Dose Bands. See GAST DSG – Dose Banding document for more information Flush after each medication: 50 mL over 6 minutes (500 mL/hr) In the event of an infusion-related hypersensitivity reaction, refer to the ‘Hypersensitivity Reaction Standing Order’ Please refer to CCMB
    [Show full text]
  • Situation De La Chimiothérapie Des Cancers Rapport 2012
    Chimiotherapie-2012_44 pages 19/07/13 10:35 Page1 Mesure 21 SOINS Situation de la chimiothérapie COLLECTION des cancers États des lieux & des connaissances RAPPORT 2012 ANALYSE DES TENDANCES RÉCENTES DE LA PRATIQUE ET DES DÉPENSES DE LA CHIMIOTHÉRAPIE DES CANCERS EN FRANCE CYTOTOXIQUES, AUTRES ANTICANCÉREUX, THÉRAPIES CIBLÉES (INHIBITEURS DE TYROSINES KINASES ET APPARENTÉS, ANTICORPS MONOCLONAUX) ET HORMONOTHÉRAPIES www.e-cancer.fr Chimiotherapie-2012_44 pages 19/07/13 10:35 Page2 2 SITUATION DE LA CHIMIOTHÉRAPIE DES CANCERS RAPPORT 2012 L’Institut national du cancer est l’agence nationale sanitaire et scientifique chargée de coordonner la lutte contre le cancer en France. Ce document est téléchargeable sur le site : www.e-cancer.fr CE DOCUMENT S’INSCRIT DANS LA MISE EN ŒUVRE DU PLAN CANCER 2009-2013. Mesure 21 : Garantir un égal accès aux traitements et aux innovations Action 21.1 : Faciliter l’accès aux traitements par molécules innovantes. Intégrer dans le rapport annuel de l’INCa un rapport de situation sur les molécules anticancéreuses. COORDINATION DU RAPPORT l Dr Natalie HOOG LABOURET, Pôle Recherche et Innovation, responsable de la Mission Réforme du Médicament l Thomas MORTIER, Pôle Recherche et Innovation, Mission Réforme du Médicament ANALYSE DES DONNÉES l Dr Christine LE BIHAN-BENJAMIN, Pôle Santé Publique et Soins, Département Observation, Veille et Innovation l Mathieu ROCCHI, Pôle Santé Publique et Soins, Département Observation, Veille et Innovation l Natalie VONGMANY, Pôle Santé Publique et Soins, Département Observation,
    [Show full text]
  • Or Irinotecan-Based Chemotherapy After Curative Resection of Synchronous Liver Metastases from Colorectal Cancer
    ANTICANCER RESEARCH 33: 3317-3326 (2013) Efficacy of Postoperative Oxaliplatin- or Irinotecan-based Chemotherapy After Curative Resection of Synchronous Liver Metastases from Colorectal Cancer HUNG-CHIH HSU1,2, WEN-CHI CHOU1,2, WEN-CHI SHEN1,2, CHIAO-EN WU1,2, JEN-SHI CHEN1,2, CHI-TING LIAU1,2, YUNG-CHANG LIN1,2 and TSAI-SHENG YANG1,2 1Division of Hematology-Oncology, Chang Gung Memorial Hospital at Linkou, Kwei-Shan, Tao-Yuan, Taiwan, R.O.C.; 2College of Medicine, Chang Gung University, Kwei-Shan, Tao-Yuan, Taiwan, R.O.C. Abstract. Background: Postoperative 5-fluorouracil (5-FU)- to more favorable RFS than 5-FU/LV following curative based chemotherapy improves survival after resection of resection of synchronous CRLM. synchronous liver metastases from colorectal cancer (CRLM). We retrospectively assessed the efficacy of postoperative Colorectal cancer (CRC) is one of the leading causes of cancer- chemotherapy with a modern regimen containing of related mortality, accounting for more than 600,000 deaths oxaliplatin or irinotecan after curative resection of annually worldwide (1-3). In Taiwan, it is the second most synchronous CRLM. Patients and Methods: Seventy-two common type of cancer in men and women, after hepatocellular patients who received postoperative chemotherapy following carcinoma and breast cancer, respectively (4). The liver is the curative resection of synchronous CRLM were analyzed. most common site of metastasis in CRC (50-60% of cases). Patients were categorized into fluorouracil plus leucovorin (5- One-third of patients have liver metastases at the time of FU/LV, n=25), irinotecan-based regimen (FOLFIRI/IFL, diagnosis (synchronous) and two-thirds develop metastases n=21) and oxaliplatin-based regimen (FOLFOX, n=26) during the disease course (metachronous) (5).
    [Show full text]
  • FOLFIRI (Irinotecan / Modified De Gramont)
    FOLFIRI (Irinotecan / Modified De Gramont) DRUG ADMINISTRATION SCHEDULE Day Drug Dose Route Diluent & Rate Glucose 5% 500ml Infusion Fast Running for Line Flush Ondansetron 8mg IV bolus Via glucose drip Dexamethasone 8mg Oral /Slow bolus/15 min infusion Calcium Leucovorin 250ml Glucose 5% over 2 hours 300mg IV Infusion (folinic acid) concurrent with irinotecan Day 1 2 IV 250ml Glucose 5% over 2 hours 180mg/m Irinotecan Infusion concurrent with folinic acid Glucose 5% 500ml Infusion Line Flush 2 5 Fluorouracil 400 mg/m IV bolus Over 5 minutes via Sodium Chloride 0.9% over 46 2400 mg/m2 5 Fluorouracil infusor hours Day 3 Attend ward/clinic for removaldevice of 5-FU infusor device *Ondansetron IV must be infused over 15 minutes in patients over 65 years of age. PREMEDICATION *If acute cholinergic syndrome appears atropine sulphate 250micrograms should be administered by subcutaneous injection unless clinically contraindicated. The manufacturer recommends the use of prophylactic atropine sulphate with subsequent doses of irinotecan. CYCLE LENGTH AND NUMBER OF DAYS Every 14 days APPROVED INDICATIONS First line for advanced colorectal cancer RECOMMENDED TAKE HOME MEDICATION Ondansetron 8mg twice daily for 2 days Dexamethasone 4mg twice daily for 1 day Metoclopramide 10mg three times daily as required Loperamide as required (4mg after first loose stool and 2mgs every 2 hours, to a maximum of 16 (2mg) tablets in 24 hours. For diarrhoea lasting greater than 24 hours give ciprofloxacin 250mg BD. Suggested antiemetic regimen - may vary with local practice. See CINV policy for more details INVESTIGATIONS / MONITORING REQUIRED FBC, U&E, LFT’s & tumour markers as appropriate prior to each course of chemotherapy FBC on the day of chemotherapy Where CEA is elevated this should be measured before each cycle (no need to await result before proceeding with treatment).
    [Show full text]
  • Download FOLFIRI Chemotherapy
    Mouth sores You mouth may become sore or dry after your treatment. Mouth problems can be caused by the chemo. Tell your nurse or doctor if you have this FOLFIRI Chemotherapy problem, as they can prescribe special mouthwashes and medicine to help. It is important to avoid hot, spicy or acidic foods. Steps to provide good mouth care: What is chemotherapy? • Use a soft toothbrush when brushing your teeth to prevent sore gums Chemotherapy is a method of treating cancer by using drugs. and bleeding. Combinations of chemotherapy drugs are often used in treating cancer. Use toothpaste for sensitive teeth if normal toothpaste bothers you. • • Floss gently, avoid rough flossing as your gums may be very sensitive and can easily bleed. What is FOLFIRI? • Brush and rinse your dentures after eating. Remove your dentures while sleeping. FOLFIRI is a combination of chemotherapy (chemo) drugs used in • Rinse your mouth at least 4 times a day. Use baking soda or salt and the treatment of cancer of the bowel. water solution. Mix a teaspoonful baking soda or salt into 1 cup (250ml) FOLFIRI chemo is given through an intravenous line (IV). The type of IV is of water. You may also use commercial mouthwash such as Biotene. called a PICC line. PICC stands for Peripherally Inserted Central Catheter. DO NOT use products which contain alcohol such as Listerine or Scope The PICC line is put in your upper arm and stays in place for your entire because the alcohol will worsen pain if there are any open sores. chemo treatment. More information about the PICC line and how it is put into your arm will be provided to you by your primary team.
    [Show full text]
  • For Health Professionals Who Care for Cancer Patients February 2007 Website Access At
    Volume 10, Number 2 for health professionals who care for cancer patients February 2007 Website access at http://www.bccancer.bc.ca/HPI/ChemotherapyProtocols/stupdate.htm I NSIDE THIS ISSUE Editor’s Choice: Guidelines for the Use of GOCXRADC, GOENDCAT, GOEP, GOOVCATM, Bevacizumab in Metastatic Colorectal Cancer, GOOVCATR, GOOVCATX, UGUAJPG, GUBCG, Communities Oncology Network Contact GUBCV, GUBEP, GUBP, GUBPW, GUEP, GUKIFN, Information on Website, Highlights of Changes in GUPDOC, GUPKETO, GUPMX, GUSCARB, Protocols and Pre-Printed Orders GUSCCAVE, GUVEIP, LKCMLI, LUNAVP, Cancer Management Guidelines – Hepatitis B ULUAVERL, ULUGEF, LYABVD, ULYALEM, LYCDA, Reactivation Consult LYCHLOR, LYCHOP, LYCHOPR, LYCODOXMR, LYCSPA, LYCVP, LYCVPPABO, LYCVPR, LYCYCLO, Cancer Drug Manual: Complete Revision: LYECV, LYFLU, LYGDP, LYHDMTXP, Fludarabine Limited Revision: Alemtuzumab, LYHDMTXR, LYIT, ULYMFBEX, ULYMFECP, Bevacizumab, Imatinib, Leucovorin, Rituximab, LYPALL, ULYRICE, LYRITB, LYRITUX, LYRITZ, Chemotherapy Preparation and Stability Chart ULYRMTN, LYSNCC, UMYBORTEZ, MYMP, Nursing Resources of the Month: Webcast: Clinical UMYTHALID, SAAVGI Breakthroughs in EGFR Inhibition Website Resources Focus on: Understanding Targeted Drug Therapies Appendix: Understanding Targeted Drug Therapies List of New and Revised Protocols, Pre-Printed Orders and Patient Handouts: Revised: BRAJDTFEC, BRLAACDT, GOCXCAT, IN TOUCH phone list is provided if additional information is needed. EDITOR’S CHOICE GUIDELINES FOR THE USE OF BEVACIZUMAB (AVASTIN®) IN METASTATIC
    [Show full text]
  • Combination of Small-Molecule Kinase Inhibitors and Irinotecan in Cancer Clinical Trials: Efficacy and Safety Considerations
    1623 Original Article Combination of small-molecule kinase inhibitors and irinotecan in cancer clinical trials: efficacy and safety considerations Ganessan Kichenadasse, Arduino Mangoni, John Miners Department of Clinical Pharmacology, Flinders University, Adelaide, Australia Contributions: (I) Conception and design: G Kichenadasse; (II) Administrative support: G Kichenadasse, J Miners; (III) Provision of study materials or patients: None; (IV) Collection and assembly of data: G Kichenadasse; (V) Data analysis and interpretation: All authors; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors. Correspondence to: Dr. Ganessan Kichenadasse. Department of Clinical Pharmacology, Flinders University, Bedford Park, SA 5042, Australia. Email: [email protected]. Background: The combination of small-molecule kinase inhibitors (KI) and the cytotoxic chemotherapy drug irinotecan, albeit studied extensively in both pre-clinical and clinical studies, has not been adopted in clinical practice. We describe the available evidence regarding the efficacy and safety of the combination of KI/irinotecan and explore the possible reasons for its failure to be translated into clinical practice. Methods: Relevant in vitro and in vivo studies were identified from Medline and abstracts of the American Society of Clinical Oncology (ASCO) annual meetings published from inception until June 2017. The results of studies for the combination of irinotecan and KI in cell lines, animal models and human trials are summarized. Results: The majority of KIs exhibit synergistic activity with irinotecan in tumour cell lines. However, published phase I/II clinical trials in cancer patients failed to show good tolerability due to the overlapping toxicity of the combination, particularly diarrhoea and neutropenia. KIs influence the metabolism of the active metabolite SN-38 [through UDP-glucuronosyl transferase 1A1 (UGT1A1) inhibition and impaired transport] resulting in increased exposure and toxicity related to irinotecan.
    [Show full text]
  • View PDF of HOPA News, Vol. 17, No. 4
    HOPA NEWS Pharmacists Optimizing Cancer Care VOLUME 17 | ISSUE 4 Oncology Pharmacy and COVID-19: Perspectives from an Early Epicenter page 3 HOPA 22 A 2020 View on Updates in the 32 A Novel Book Club Hematology/Oncology Treatment of Lung Cancer Regimen Pharmacy Association FEATURE HOPA Hematology/Oncology VOLUME 17 | ISSUE 4 Pharmacy Association Pharmacists Optimizing Cancer Care® HOPA Publications Committee Christan M. Thomas, PharmD BCOP, Editor Renee McAlister, PharmD BCOP, CONTENTS Associate Editor 3 Feature Lisa Cordes, PharmD BCOP BCACP, Oncology Pharmacy and COVID-19: Perspectives Associate Editor from an Early Epicenter Andrea Clarke, PharmD BCOP 5 Reflection on Personal Impact and Growth Jeff Engle, PharmD MS From Skeptic to Believer: How an oncology pharmacist, mom, and recovering workaholic learned Ashley E. Glode, PharmD BCOP to embrace integrative medicine Sidney V. Keisner, PharmD BCOP 7 Practice Management Chair Time Optimization Chung-Shien Lee, PharmD BCOP BCPS 11 Heather N. Moore, PharmD BCOP Quality Initiatives Pharmacy Telehealth Services – Efficient and Safe Gregory Sneed, PharmD Quality Care Before and During the COVID-19 Pandemic Diana Tamer, PharmD BCOP 13 Clinical Pearls Jennifer Zhao, PharmD BCOP Chemotherapy and Immune Checkpoint Inhibitor Combination Regimens: How do we manage corticosteroid use to prevent adverse effects from chemotherapy? HOPA News Staff 20 The Resident’s Cubicle Sally Barbour, PharmD BCOP, Board Liaison Exploring Teaching Opportunities During Residency Training Michelle Sieg, Communications
    [Show full text]
  • Negative Change Add Inclusion Criteria
    Policy Drug(s) Type of Change Brief Description of Policy Change new policy Elitek (rasburicase) n/a n/a new policy Retevmo (selpercatinib) n/a n/a new policy Tabrecta (capmatinib) n/a n/a new policy Trodelvy (govitecan-hziy) n/a n/a new policy Qinlock (ripretinib) n/a n/a UM ONC_1048 Campath (alemtuzumab) Archive Campath is no longer being used for any Hematology Oncology indications. Remove inclusion criteria: ALL: Induction, consolidation, maitenance, relapsed/refractory combination removed and use is supported as a part of a multi-agent chemotherapy regimen, for all sub-types of ALL, for induction/consolidation therapy, and for therapy of relapsed refractory disease NHL: Induction, consolidation, maitenance, relapsed/refractory combination removed and use is supported for extra- nodal NK/T-cell lymphoma (nasal type) and as a part of a multi-agent chemotherapy regimen for either first line therapy and/or therapy for relapsed /refractory disease. UM ONC_1063 Oncaspar (pegaspargase) Positive change Remove exclusion criteria: History of serious thrombosis, pancreatitis, or hemorrhagic events with L-asparaginase (ELSPAR) therapy. UM ONC_1064 Oncaspar (pegaspargase) Positive change Add exclusion criteria: Dosing exceeds single dose limit of Trastuzumab 8 mg/kg for the loading dose, 6 mg/kg for UM ONC_1134 Trastuzumab products Negative change subsequent doses when given every 3 weeks; 4 mg/kg for the loading dose and 2 mg/kg for the weekly dose. Remove exclusion criteria: Velcade (bortezomib) is being used after disease progression on another Velcade-based regimen. UM ONC_1136 Velcade (bortezomib) Positive change Add inclusion criteria: Multiple Myeloma: - NOTE: The preferred agent, per NCH policy, is generic bortezomib over brand bortezomib (Velcade) for all indications, unless there are contraindications or intolerance to generic bortezomib.
    [Show full text]
  • Hypertension Secondary to Anti-Angiogenic Therapy: Experience with Bevacizumab
    ANTICANCER RESEARCH 27: 3465-3470 (2007) Hypertension Secondary to Anti-angiogenic Therapy: Experience with Bevacizumab AMITKUMAR PANDE1, JEFFREY LOMBARDO2, EDWARD SPANGENTHAL1 and MILIND JAVLE3 Departments of 1Medicine and 2Pharmacy, Roswell Park Cancer Institute, Elm and Carlton Sts, Buffalo, NY 14263; 3Department of GI Medical Oncology, UT-MD Anderson Cancer Institute, Unit 426, 1515 Holcombe Ave, Houston, TX 77030, U.S.A. Abstract. Background: Hypertension (HT) is a common single agents or in combination with cytotoxic chemotherapy complication of anti-angiogenic therapy. Its incidence, treatment and radiotherapy so as to achieve synergistic or additive and complications are undefined. Patients and Methods: effects. Hypertension is a consistent toxicity of patients Retrospective review of patients treated with bevacizumab (BV) treated with anti-angiogenic agents and the incidence of this from 2003-5. Common toxicity criteria (CTC) for adverse events complication is likely to increase with increasing use of anti- version 3.0 were used. Results: Fifty-five out of the 154 patients angiogenic therapy. No current guidelines exist regarding treated with BV (35%) experienced HT. Eleven (20%) developed the management of hypertension in this situation. The a new onset HT and 44 (80%) experienced an exacerbation of widest experience with anti-angiogenic therapy is with pre-existing HT. HT developed after a median of 11 weeks at a bevacizumab (BV), a recombinant humanized monoclonal median BV dose of 10 mg/kg. HT severity was grade 1 (n=1), antibody. BV binds to and inhibits the activity of VEGF grade 2 (n=29) or grade 3 (n=22); 3 experienced hypertensive which results in failure of interaction between VEGF and complications.
    [Show full text]
  • Metastatic Colorectal Cancer. First Line Therapy for Unresectable Disease
    Journal of Clinical Medicine Review Metastatic Colorectal Cancer. First Line Therapy for Unresectable Disease Jorge Aparicio 1,* , Francis Esposito 2 , Sara Serrano 3, Esther Falco 4, Pilar Escudero 5, Ana Ruiz-Casado 6 , Hermini Manzano 7 and Ana Fernandez-Montes 8 1 Department of Medical Oncology, Hospital Universitario y Politecnico La Fe, E-46007 Valencia, Spain 2 Department of Medical Oncology, Hospital Clinic, E-08041 Barcelona, Spain; [email protected] 3 Department of Medical Oncology, Hospital Universitario Sant Joan de Reus, E-43204 Reus, Spain; [email protected] 4 Department of Medical Oncology, Hospital Son Llatzer, E-07004 Palma de Mallorca, Spain; [email protected] 5 Department of Medical Oncology, Hospital Clínico Universitario Lozano Blesa, E-50002 Zaragoza, Spain; [email protected] 6 Department of Medical Oncology, Hospital Universitario Puerta de Hierro, E-28220 Madrid, Spain; aruiz.hfl[email protected] 7 Department of Medical Oncology, Hospital Quirón Salud Palmaplanas, E-07004 Palma de Mallorca, Spain; [email protected] 8 Department of Medical Oncology, Complejo Hospitalario de Orense, E-32001 Orense, Spain; [email protected] * Correspondence: [email protected]; Tel.: +34-6-606563508 Received: 2 November 2020; Accepted: 26 November 2020; Published: 30 November 2020 Abstract: Colorectal cancer (CRC) is a commonly diagnosed malignancy. The prognosis of patients with unresectable, metastatic colorectal cancer (mCRC) is dismal and medical treatment is mainly palliative in nature. Although chemotherapy remains the backbone of treatment, the landscape is changing with the understanding of its heterogeneity and molecular biology. First-line therapy relies on a combination of chemotherapy and targeted therapies, according to clinical patient characteristics and tumor molecular profile.
    [Show full text]
  • Trailblazing Strategies for Cancer Treatment
    cancers Review TRAILblazing Strategies for Cancer Treatment Anna-Laura Kretz 1, Anna Trauzold 2,3, Andreas Hillenbrand 1, Uwe Knippschild 1, Doris Henne-Bruns 1, Silvia von Karstedt 4,5 and Johannes Lemke 1,* 1 Department of General and Visceral Surgery, Ulm University Hospital, Albert-Einstein-Allee 23, 89081 Ulm, Germany; [email protected] (A.-L.K.); [email protected] (A.H.); [email protected] (U.K.); [email protected] (D.H.-B.) 2 Institute for Experimental Cancer Research, University of Kiel, 24105 Kiel, Germany; [email protected] 3 Clinic for General Surgery, Visceral, Thoracic, Transplantation and Pediatric Surgery, University Hospital Schleswig-Holstein, 24105 Kiel, Germany 4 Department of Translational Genomics, University Hospital Cologne, Weyertal 115b, 50931 Cologne, Germany; [email protected] 5 Cologne Excellence Cluster on Cellular Stress Response in Aging-Associated Diseases (CECAD), University of Cologne, Joseph-Stelzmann Straße 26, 50931 Cologne, Germany * Correspondence: [email protected] Received: 11 March 2019; Accepted: 26 March 2019; Published: 30 March 2019 Abstract: In the late 1990s, tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL), a member of the TNF-family, started receiving much attention for its potential in cancer therapy, due to its capacity to induce apoptosis selectively in tumour cells in vivo. TRAIL binds to its membrane-bound death receptors TRAIL-R1 (DR4) and TRAIL-R2 (DR5) inducing the formation of a death-inducing signalling complex (DISC) thereby activating the apoptotic cascade. The ability of TRAIL to also induce apoptosis independently of p53 makes TRAIL a promising anticancer agent, especially in p53-mutated tumour entities.
    [Show full text]